Alzamend Neuro, Inc. (ALZN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Alzamend Neuro, Inc., a Delaware corporation and emerging growth company, on July 8, 2024. The report details the results of a Special Meeting of Stockholders held on the same date. The Company's common stock trades on The Nasdaq Capital Market under the symbol "ALZN."
Key Financial Metrics
The filing does not provide specific financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and capital structure changes resulting from the stockholder vote.
Material Changes
The primary material event reported is the approval by stockholders of a proposal to convert Series A Preferred Stock into Common Stock and warrants. Key details include:
- Proposal Approved: Conversion of Series A Preferred Stock pursuant to Rule 5635 of the Nasdaq Stock Market.
- Transaction Value: The conversion relates to a total purchase price of up to $25,000,000.00 under a Securities Purchase Agreement dated May 8, 2024.
- Voting Results:
- For: 5,356,845 votes
- Against: 79,371 votes
- Abstain: 3,043 votes
- Broker Non-Votes: 0
- Capital Structure Context: As of the record date (May 29, 2024), the Company had 7,376,011 shares of Common Stock outstanding, 78.8236 shares of Series A Preferred Stock (voting power equivalent to 1,375,310 Common shares), and 2,100 shares of Series B Convertible Preferred Stock (convertible into 2,100,000 Common shares).
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future financial guidance, operational outlook, or specific risk factors. The document serves strictly to disclose the outcome of the stockholder vote and lists standard exhibits (Inline XBRL cover page and interactive data file).
Investor Verification Checklist
- Verify the final conversion ratio and number of Common Stock shares issued upon the conversion of Series A Preferred Stock.
- Review the definitive proxy statement (Schedule 14A) filed on May 31, 2024, for detailed terms of the $25 million Securities Purchase Agreement.
- Confirm the impact of the Series A conversion on total outstanding share count and potential dilution to existing common shareholders.
- Check subsequent filings for the issuance of the warrants mentioned in the approved proposal.